Survival variability of controls and definition of imaging endpoints for longitudinal follow-up of pancreatic ductal adenocarcinoma in rats.
Fiche publication
Date publication
janvier 2017
Journal
Journal of cancer research and clinical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MUTTER Didier
Tous les auteurs :
Akladios C, Ignat M, Mutter D, Aprahamian M
Lien Pubmed
Résumé
The 3Rs guideline is the gold standard for ethics in animal experimentation. Two of those rules, namely refinement and reduction, require further improvement. The objective of this study was to define pathways to better compliance with these prerequisites. Two methods which move us in this direction are: (1) using small animal imaging techniques for pancreatic ductal adenocarcinoma (PDAC) follow-up and (2) reduction of the number of control animals included in a study of PDAC progression under treatment.
Mots clés
Animals, Antimetabolites, Antineoplastic, pharmacology, Carcinoma, Pancreatic Ductal, diagnostic imaging, Cell Line, Tumor, Deoxycytidine, analogs & derivatives, Drug Screening Assays, Antitumor, Follow-Up Studies, Longitudinal Studies, Male, Pancreatic Neoplasms, diagnostic imaging, Rats, Inbred Lew, Survival Rate, X-Ray Microtomography
Référence
J. Cancer Res. Clin. Oncol.. 2017 Jan;143(1):29-34